ANVS vs. KZR, CALC, KRON, JAGX, ELDN, MURA, CELU, MNOV, SCYX, and IMMX
Should you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include Kezar Life Sciences (KZR), CalciMedica (CALC), Kronos Bio (KRON), Jaguar Health (JAGX), Eledon Pharmaceuticals (ELDN), Mural Oncology (MURA), Celularity (CELU), MediciNova (MNOV), SCYNEXIS (SCYX), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical preparations" industry.
Kezar Life Sciences (NASDAQ:KZR) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.
67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 7.9% of Kezar Life Sciences shares are held by company insiders. Comparatively, 38.3% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Annovis Bio's return on equity of -43.08% beat Kezar Life Sciences' return on equity.
Kezar Life Sciences received 115 more outperform votes than Annovis Bio when rated by MarketBeat users. However, 94.74% of users gave Annovis Bio an outperform vote while only 57.83% of users gave Kezar Life Sciences an outperform vote.
Annovis Bio has lower revenue, but higher earnings than Kezar Life Sciences. Annovis Bio is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kezar Life Sciences and Kezar Life Sciences both had 3 articles in the media. Annovis Bio's average media sentiment score of 0.00 equaled Kezar Life Sciences'average media sentiment score.
Kezar Life Sciences currently has a consensus target price of $11.00, suggesting a potential upside of 1,246.39%. Annovis Bio has a consensus target price of $25.25, suggesting a potential upside of 318.74%. Given Annovis Bio's higher possible upside, equities research analysts clearly believe Kezar Life Sciences is more favorable than Annovis Bio.
Kezar Life Sciences has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.
Summary
Kezar Life Sciences beats Annovis Bio on 8 of the 14 factors compared between the two stocks.
Get Annovis Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Annovis Bio Competitors List
Related Companies and Tools
